Michael Kolodziej, MD, National Medical Director for Oncology Strategies, Aetna, says that the rapid emergence of precision medicine was one of the more interesting topics discussed at the ASCO 2013 Annual Meeting.
Michael Kolodziej, MD, National Medical Director for Oncology Strategies, Aetna, says that the rapid emergence of precision medicine was one of the more interesting topics discussed at the ASCO 2013 Annual Meeting. Dr Kolodziej discussed the importance of understanding how the information on specific genetic mutations to tailor therapy that is optimal for each patient will be used. "I think the discussion about how to develop the necessary quantum of information that you need to prove that it actually works," said Dr Kolodziej "Because from a payer perspective clinical utility is going to be the most important thing."
This video was taken on June 1, 2013, at the ASCO Annual Meeting 2013 in Chicago, IL.
Results Show Strong Responses for Brentuximab Vedotin Plus Nivolumab Combo in Patients With cHL
December 11th 2023Use of an antibody drug conjugate and a PD-1 inhibitor brings complementary mechanisms together while eliminating the most toxic agent that has been used in combinations to treat classic Hodgkin lymphoma (cHL).
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen